Medical affairs teams are increasingly using artificial intelligence to manage scientific information, accelerate evidence workflows, monitor external developments, and support faster decision-making. The opportunity is significant, but pharmaceutical organisations cannot approach AI adoption in medical affairs like a general productivity initiative. Scientific accuracy, source traceability, medical review, data privacy, regulatory expectations, and human oversight all need to be considered from the beginning.
The most effective medical affairs AI tools therefore do more than generate summaries or answer questions. They help teams discover relevant evidence, connect scientific information, maintain source attribution, and support controlled workflows where qualified professionals remain accountable. For organisations building enterprise AI capabilities, an AI governance platform regulated industries can provide a governance layer for managing these requirements across functions.
This article explores the most valuable AI use cases for medical affairs in 2026, the compliance guardrails pharmaceutical organisations should establish, the role of AI in MLR workflows, and how companies can build a scalable medical affairs platform without compromising scientific quality.
1. Why AI Is Becoming Important for Medical Affairs
Medical affairs operates at the intersection of scientific evidence, clinical development, external experts, healthcare professionals, and internal stakeholders. The volume of information teams must monitor continues to expand across publications, clinical trials, congresses, treatment guidelines, regulatory communications, real-world evidence, competitive developments, and internal scientific documentation.
The scale of this challenge is increasingly reflected in industry research. A 2026 global survey of 367 Medical Affairs professionals across 48 countries found that 74% believed AI would have an impactful or highly impactful role in Medical Affairs and the MSL function, while 87% considered learning about AI important or very important to remaining competitive. Yet only 27% of respondents were currently using AI for KOL engagement, highlighting the gap between perceived potential and practical adoption.
Investment expectations point in the same direction. ZS's 2025 Medical Affairs outlook found that nearly 90% of respondents expected their organizations to invest in generative AI for data analysis and insights generation, with applications also expected across scientific literature review, summarization, content creation, and personalization.
The broader life sciences market is also increasing its focus on AI. Deloitte reported that nearly 60% of surveyed life sciences executives planned to increase generative AI investments across the value chain, while its analysis estimated that AI investments by biopharma companies could generate value equivalent to up to 11% of revenue over five years across functional areas.
These figures suggest that AI is moving beyond experimentation and becoming part of the strategic discussion around how Medical Affairs operates.
Traditional workflows often depend on literature databases, spreadsheets, email alerts, internal repositories, manual searches, and specialist vendors. These approaches remain useful, but they become difficult to scale as therapeutic areas and information sources increase.
AI can change this operating model.
Rather than asking medical professionals to manually locate, consolidate, classify, and summarise every relevant source, medical affairs AI tools can automate information-intensive activities while keeping scientific interpretation with qualified professionals.
Practical applications include:
Scientific literature monitoring
Evidence discovery and summarisation
Clinical trial monitoring
Congress intelligence
Medical information support
KOL and scientific expert intelligence
Internal scientific knowledge discovery
Evidence synthesis
Content quality checks
Medical affairs AI tools are AI-enabled technologies that help pharmaceutical teams manage scientific information, analyse evidence, monitor developments, and support knowledge discovery.
Examples in the market include Microsoft 365 Copilot for enterprise productivity, AlphaSense for research and market intelligence, Iris.ai for scientific literature discovery, and Veeva Vault Medical for medical content and information workflows.
For Medical Affairs, however, the key difference between a generic chatbot and an enterprise medical affairs platform is trust and governance. A suitable platform should provide:
Evidence retrieval from trusted sources
Source traceability for important claims
Scientific context across products, trials, publications, and experts
Human oversight for scientific interpretation
Governance and access controls
Auditability of AI-assisted workflows
Platforms such as Pienomial extend this approach by connecting scientific evidence, knowledge, and AI-assisted research workflows, helping Medical Affairs teams discover, synthesise, and contextualise information across complex life sciences environments.
The goal is not simply to use AI, but to make scientific information faster to discover, easier to verify, and safer to use at enterprise scale.
3. Key Medical Affairs AI Use Cases in 2026
Literature Monitoring and Evidence Discovery
Medical affairs professionals need to monitor an expanding scientific literature landscape.
AI can identify potentially relevant publications based on therapeutic areas, products, mechanisms, indications, biomarkers, endpoints, competitors, and other scientific concepts.
Instead of requiring analysts to manually review hundreds of search results, AI can classify and prioritise information according to predefined criteria.
The medical professional can then review the underlying publication and determine its scientific relevance.
This approach can be particularly valuable when teams need to monitor multiple indications or large scientific landscapes without expanding manual review capacity at the same rate.
Scientific Literature Summarisation
AI can reduce the time required for initial literature processing by summarising study objectives, patient populations, study design, endpoints, findings, safety observations, limitations, and relevant comparisons.
However, the summary should remain connected to the original publication.
A medical affairs professional should be able to inspect the evidence rather than relying exclusively on an AI-generated interpretation. The value comes from reducing the time required to process information, not from removing scientific review.
Clinical Trial Intelligence
AI can monitor clinical trial information and identify changes relevant to medical affairs, including new registrations, recruitment changes, protocol amendments, endpoint changes, study populations, competitor programmes, and trial results.
A dedicated clinical trial intelligence capability can help life sciences teams structure and monitor trial information so that important developments are easier to identify and interpret.
For medical affairs teams operating in competitive therapeutic areas, this can provide a faster view of changes in the scientific landscape and create a more consistent evidence-monitoring workflow.
Congress Monitoring
Major medical congresses generate enormous volumes of abstracts, posters, presentations, and scientific discussions.
AI can help classify conference information according to therapeutic area, product, competitor, mechanism, endpoint, or other predefined priorities.
This allows medical teams to focus their attention on developments most relevant to their responsibilities instead of manually reviewing every available item.
AI can assist medical information teams by retrieving approved evidence and organising information into structured response frameworks.
This use case requires strong controls. AI should not independently provide unreviewed medical advice or generate unsupported scientific claims. Qualified professionals should remain responsible for the final response.
A controlled workflow can instead help professionals find relevant evidence more quickly and prepare information for appropriate review.
KOL and Scientific Expert Intelligence
AI can help medical affairs teams understand external scientific activity by analysing publications, congress participation, clinical trial involvement, research interests, institutional affiliations, and scientific collaborations.
The purpose is not to automate expert engagement. It is to provide a more current evidence base for understanding scientific communities and preparing for meaningful interactions.
4. What Regulators Are Signalling About AI
AI adoption in life sciences is increasingly being approached through risk-based and human-centric principles.
The European Medicines Agency's reflection paper on AI in the medicinal product lifecycle addresses applications across the medicines lifecycle and highlights the need to manage risks based on factors such as context of use, data quality, model performance, and potential regulatory or patient impact. It also emphasises that AI use should remain aligned with legal, ethical, technical, scientific, and regulatory standards. [1]
EMA and the U.S. FDA published ten guiding principles for good AI practice in drug development in January 2026. These principles cover human-centric design, risk-based approaches, adherence to standards, clear context of use, multidisciplinary expertise, data governance and documentation, model development, performance assessment, lifecycle management, and clear essential information. [2]
The FDA's January 2025 draft guidance on AI supporting regulatory decision-making also proposes a risk-based credibility assessment framework for AI models used to generate information supporting decisions about drug and biological product safety, effectiveness, or quality. [3]
These developments reinforce an important principle for medical affairs: AI governance should be incorporated into the workflow and architecture rather than added after deployment.
5. AI Compliance Guardrails Pharma Teams Need
Strong AI compliance guardrails pharma teams establish should address several areas simultaneously.
Source Governance
AI systems should have defined rules governing which sources they can access.
A peer-reviewed publication, regulatory document, clinical trial registry, internal medical document, and third-party commentary should not automatically be treated as equivalent evidence.
Source type, provenance, currency, and relevance should be considered within the workflow.
Human Review
AI-generated information should not automatically become externally usable medical content.
Human review remains important for scientific communications, medical information responses, regulatory materials, patient-facing information, external expert communications, and other higher-risk activities.
The required level of review should depend on the intended use and associated risk.
Traceability
An important AI output should be traceable to its supporting evidence.
Users should ideally be able to determine:
Which source supports the claim.
Whether the source is current.
Whether AI summarised or interpreted the evidence.
Whether additional verification is required.
Who reviewed the output when human review was required.
Access Controls
Not every employee needs access to every AI workflow or dataset.
Enterprise implementations should define permissions based on roles, functions, therapeutic areas, data sensitivity, and other organisational requirements.
Data Privacy and Security
Organisations should establish clear rules governing what information can enter an AI system, where data is processed, who can access outputs, how information is retained, and whether data can be used for model training.
The NIST Generative AI Profile provides a cross-sector resource for identifying and managing generative AI risks across the AI lifecycle, including risk management practices aligned with organisational goals and requirements. [4]
6. Preventing Hallucinations in Medical Affairs AI
Hallucination remains a significant concern in scientific applications.
An AI system can produce an answer that sounds authoritative while containing an unsupported statement, incorrect interpretation, or inaccurate citation.
For medical affairs, this becomes particularly problematic when AI-generated content is treated as verified evidence.
A robust medical affairs platform should therefore reduce dependence on model memory by connecting AI generation with governed evidence retrieval.
Important controls include:
Retrieval before generation: Relevant evidence should be retrieved before an answer is generated.
Claim-level sourcing: Important scientific statements should be connected to supporting evidence.
Uncertainty handling: Where evidence is insufficient, the system should indicate limitations rather than generate a confident answer.
Source prioritisation: Primary, authoritative, and approved sources should receive appropriate priority.
Human verification: Higher-risk outputs should be reviewed by appropriately qualified professionals.
EMA's current AI resources for large language models similarly emphasise safe data input, critical evaluation and cross-checking of outputs, continuous learning, and knowing whom to consult when concerns arise. [5]
The goal is to make AI an evidence-support system rather than an uncontrolled answer generator.
7. Where MLR Review AI Fits
MLR review AI can help pharmaceutical teams identify potential issues before content reaches formal medical, legal, and regulatory review.
An AI-assisted workflow could flag:
Unsupported claims
Missing citations
Potentially outdated evidence
Inconsistent terminology
References that do not support a claim
Conflicting statements
Content requiring additional substantiation
This does not mean AI should replace the MLR committee.
Instead, AI can operate as a pre-review quality layer, allowing reviewers to spend more time on substantive scientific, legal, and regulatory judgment.
The strongest approach positions AI as a review assistant, not an autonomous approval mechanism. This distinction is especially important where content could influence external scientific communication or other regulated activities.
8. Building a Digital Strategy and Innovation Model
AI should not be introduced as an isolated technology project.
A successful digital strategy and innovation for medical affairs programme begins with the workflows where teams experience the greatest information burden.
A practical model involves five stages.
Stage 1: Identify High-Value Workflows
Start with repetitive, information-intensive activities such as literature monitoring, congress intelligence, evidence summarisation, or knowledge discovery.
Stage 2: Classify Risk
A literature triage workflow may have a different risk profile from AI-assisted external medical communication.
Risk classification helps determine appropriate controls, validation, review, and oversight.
Stage 3: Establish Governance
Define policies for data access, source selection, human review, AI usage, auditability, and escalation.
Stage 4: Pilot With Medical Users
Medical professionals should participate in pilots because they can identify where AI creates genuine value and where additional controls are needed.
Once individual use cases demonstrate value, organisations can connect them through common infrastructure rather than creating numerous disconnected AI applications.
This is where an enterprise platform can become more valuable than a collection of standalone tools.
Pharmaceutical organisations can purchase individual tools for literature review, summarisation, research monitoring, and content support.
However, disconnected tools can create another layer of fragmentation.
One application may store evidence in one environment, another may generate summaries without access to that evidence, and a third may use a different governance model.
A unified medical affairs platform can provide a common foundation for evidence access, governance, permissions, source controls, and AI-enabled workflows.
The broader life sciences environment also benefits when scientific intelligence is connected across medical affairs, clinical development, regulatory, market access, and competitive intelligence rather than remaining isolated within individual functions.
The benefits of a connected model include:
Consistent governance
Centralised evidence access
Common permissions
Standardised source controls
Reusable scientific context
Better auditability
Reduced duplication
Easier enterprise scaling
10. How Pienomial Supports Governed Medical Affairs AI
Pienomial's approach focuses on connecting AI capabilities with structured evidence and governed knowledge rather than treating generative AI as an isolated chatbot.
For medical affairs teams, this approach can support workflows where evidence needs to be discoverable, contextualised, and traceable across scientific and competitive information.
KnolAI can support research and intelligence workflows by helping teams monitor relevant developments, retrieve information, and structure insights from complex life sciences evidence. The focus is on helping professionals work with information more efficiently while retaining human judgment over interpretation and decisions.
The objective is not to remove medical expertise from the process. It is to provide professionals with a more efficient information layer so they can focus on scientific interpretation, external engagement, and strategic decision-making.
11. Measuring the ROI of Medical Affairs AI
The business case for AI should extend beyond hours saved.
Medical affairs organisations can measure several dimensions of value.
Time to evidence: How quickly can professionals identify and review relevant evidence?
Monitoring efficiency: How much manual effort is removed from publication, clinical trial, congress, and competitor monitoring?
Review efficiency: Does AI-assisted pre-review reduce basic issues reaching formal MLR review?
Evidence quality: Are outputs consistently connected to appropriate sources?
Knowledge reuse: Can teams access information previously buried within repositories or documents?
Decision speed: Does improved access to current intelligence enable faster responses to important developments?
Governance performance: Can the organisation demonstrate how information was sourced, processed, reviewed, and used?
In regulated environments, successful AI adoption is not simply about doing more with fewer resources. It is about improving productivity while maintaining control over the evidence and decision process.
Conclusion
The next phase of AI adoption in medical affairs will be defined less by the novelty of generative AI and more by how effectively pharmaceutical organisations integrate it into governed scientific workflows.
The most valuable medical affairs AI tools will help professionals discover evidence, monitor developments, synthesise information, identify potential issues, and access institutional knowledge while preserving source traceability and human accountability.
For pharmaceutical organisations, AI compliance guardrails pharma teams establish should be incorporated into architecture, workflows, permissions, source controls, and review processes from the beginning.
The same principle applies to MLR review AI. AI can accelerate preparation and identify potential issues, but qualified professionals should retain responsibility for decisions requiring medical, legal, or regulatory judgment.
Pienomial can support this transition by combining AI capabilities with structured intelligence and governed evidence workflows. As organisations develop their digital strategy and innovation for medical affairs, the strongest approach will combine automation with scientific discipline.
The question for 2026 is no longer simply whether medical affairs should use AI. It is whether organisations can build an AI environment that is useful enough to scale, governed enough to trust, and connected enough to become part of long-term scientific intelligence infrastructure.
CTA: Explore how Pienomial can support governed AI and evidence intelligence for life sciences teams.
